# Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

> **NCT01243359** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage I Renal Cell Cancer
- Stage II Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sunitinib malate
- **BIOLOGICAL:** bevacizumab
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis
- **OTHER:** fluorine F 18 fluorothymidine
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** computed tomography

## Key facts

- **NCT ID:** NCT01243359
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-02
- **Final completion:** —
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243359, "Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01243359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*